MedTrace Logo

Repurposing Chlorpromazine in the Treatment of Glioblastoma

NCT04224441 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-01-13

No results posted yet for this study

Summary

This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol, i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide, in newly diagnosed glioblastoma multiforme patients carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase (MGMT) gene

Conditions

Interventions

DRUG

Chlorpromazine Pill

The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide

Sponsors & Collaborators

  • Regina Elena Cancer Institute

    collaborator OTHER

  • Carlo Besta Neurological Institute

    collaborator OTHER

  • Istituto Oncologico Veneto IRCCS

    collaborator OTHER

  • Marco G Paggi, MD, PhD

    lead OTHER

Principal Investigators

  • Marco G Paggi, MD, PhD · Regina Elena Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-15
Primary Completion
2022-06-15
Completion
2022-12-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04224441 on ClinicalTrials.gov